AL amyloidosis manifesting as systemic lymphadenopathy

References

• Kyle R A, Gertz M A. Primary systemic amyloidosis. Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45–59
   PubMed Web of Science ®Google Scholar
• Buxbaum J. The amyloidoses. Rheumatology. 2nd ed., J H Klippel, P A Dieppe. Mosby, London 1998; 1–10, 8.27
   Google Scholar
• Westermark P, Benson M D, Buxbaum J N, Cohen A S, Frangione B, Ikeda S, Masters C L, Merlini G, Saraiva M J, Sipe J D. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid: J Protein Folding Disord 2005; 12: 1–4
   PubMed Web of Science ®Google Scholar
• Hoshii Y, Setoguchi M, Iwata T, Ueda J, Cui D, Kawano H, Gondo T, Takahashi M, Ishihara T. Useful polyclonal antibodies against synthetic peptides corresponding to immunoglobulin light chain constant region for immunohistochemical detection of immunoglobulin light chain amyloidosis. Pathol Int 2001; 51: 264–270
   PubMed Web of Science ®Google Scholar
• Matsuda M, Yamada T, Gono T, Shimojima Y, Ishii W, Fushimi T, Sakashita K, Koike K, Ikeda S. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis. Intern Med 2005; 44: 428–433
   PubMed Web of Science ®Google Scholar
• Gono T, Matsuda M, Shimojima Y, Ishii W, Yamamoto K, Koyama J, Sakashita K, Koike K, Itoh S, Isaka T, Ikeda S. IgM AL amyloidosis due to B cell lymphoproliferative disorder. Efficacy of high-dose melphalan followed by autologous stem cell transplantation. Amyloid: J Protein Folding Disord 2004; 11: 130–135
   PubMed Web of Science ®Google Scholar
• Matsuda M, Gono T, Shimojima Y, Ikeda S. Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis. Amyloid: J Protein Folding Disord 2003; 10: 110–116
   PubMed Web of Science ®Google Scholar
• Ko H S, Davidson J W, Pruzanski W. Amyloid lymphadenopathy. Ann Intern Med 1976; 85: 763–764
   PubMed Web of Science ®Google Scholar
• Newland J R, Linke R P, Kleinsasser O, Lennert K. Lymph node enlargement due to amyloid. Virchows Arch A 1983; 399: 233–236
   Web of Science ®Google Scholar
• Kahn H, Strauchen J A, Gilbert H S, Fuchs A. Immunoglobulin-related amyloidosis presenting as recurrent isolated lymph node involvement. Arch Pathol Lab Med 1991; 115: 948–950
   PubMed Web of Science ®Google Scholar
• Leach D B, Hester T O, Farrell H A, Chowdhury K. Primary amyloidosis presenting as massive cervical lymphadenopathy with severe dyspnea. A case report and review of the literature. Otolaryngol Head Neck Surg 1999; 120: 560–564
   Google Scholar
• Meeus G, Ponette J, Delabie J, Verschakelen J, Blockmans D. Immunoglobulin related amyloidosis presenting as isolated lymph node and pulmonary involvement. Leuk Lymphoma 2000; 38: 423–427
   PubMed Web of Science ®Google Scholar
• Hanley J P, MacLean F R, Evans J L, Colls B M, Robinson B A, Patton W N, Heaton D C. Hemorrhagic lymphadenopathy as a presenting feature of primary AL amyloidosis. Pathology 2000; 32: 21–23
   Google Scholar
• Kutlay S, Hasan T, Keven K, Nergizoglu G, Ates K, Karatan O. Primary amyloidosis presenting with massive generalized lymphadenopathy. Leuk Lymphoma 2002; 43: 1501–1503
   PubMed Web of Science ®Google Scholar
• Vogel M N, Wehrmann M, Horger M S. Massive cervical and abdominal lymphadenopathy caused by localized amyloidosis. J Clin Oncol 2007; 25: 343–344
   PubMedGoogle Scholar
• Sanchorawala V, Wright D G, Seldin D C, Dember L M, Finn K, Falk R H, Berk J, Quillen K, Skinner M. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637–642
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A, Gastineau D A, Chen M G, Ansell S M, Inwards D J, Micallef I N, Tefferi A, Litzow M R. Stem cell transplantation for management of primary systemic amyloidosis. Am J Med 2002; 113: 549–555
   PubMed Web of Science ®Google Scholar
• Gono T, Matsuda M, Dohi N, Hoshi K, Tada T, Sakashita K, Koike K, Aizawa M, Ikeda S. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med 2003; 42: 72–77
   PubMed Web of Science ®Google Scholar
• Gono T, Matsuda M, Shimojima Y, Ishii W, koyama J, Sakashita K, Koike K, Hoshii Y, Ikeda S. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis. Japanese experience and criteria for patient selection. Amyloid: J Protein Folding Disord 2004; 11: 245–256
   PubMed Web of Science ®Google Scholar
• Valente M, Roy V, Lacy M Q, Dispenzieri A, Gertz M A. Autologous stem cell transplantation and IgM amyloidosis. Leuk Lymphoma 2006; 47: 1006–1012
   PubMed Web of Science ®Google Scholar
• Gertz M A, Anagnostopoulos A, Anderson K, Branagan A R, Coleman M, Frankel S R, Giralt S, Levine T, Munshi N, Pestronk A, Rajkumar V, Treon S P. Treatment recommendations in Waldenstrom's macroglobulinemia. Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 121–126
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Zervas C, Zomas A, Kiamouris C, Viniou N A, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol 2002; 20: 2327–2333
   PubMed Web of Science ®Google Scholar